BioXcel Therapeutics’ independent Data Safety Monitoring Board (DSMB) recommended the continuation of the SERENITY At-Home Phase 3 safety trial for BXCL501, a treatment for acute agitation linked to bipolar disorders or schizophrenia. The recommendation is based on positive safety data from 178 patients, and topline results are anticipated in Q3 2025. The trial, fully enrolled in May 2025, focuses on the safety of a 120 mcg dose of BXCL501 administered at home.
This positive DSMB recommendation significantly de-risks the development of BXCL501 for at-home use. Currently, no FDA-approved treatments exist for this indication, representing a substantial unmet need for millions of patients experiencing agitation related to bipolar disorder or schizophrenia in their homes. A successful trial outcome could significantly improve the quality of life for these individuals and alleviate the burden on caregivers. Furthermore, expanding the use of BXCL501 beyond the clinically supervised setting could reduce the need for costly and potentially disruptive emergency room visits or hospitalizations.
The SERENITY trial is a double-blind, placebo-controlled study evaluating the safety of BXCL501 over a 12-week period. Patients self-administer the medication during agitation episodes, and safety data is collected throughout the trial. Exploratory endpoints include patient-reported or caregiver-reported assessments of severity and change in agitation levels two hours post-dose.
A positive safety profile from the SERENITY trial, coupled with the potential for a supplemental New Drug Application (sNDA), positions BXCL501 for a label expansion into the at-home treatment market. This could represent a significant commercial opportunity for BioXcel and solidify its position in the acute agitation treatment landscape. Positive results may also encourage further research and development into at-home treatments for other mental health conditions, potentially revolutionizing how care is delivered in this space.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
